[Therapeutic trials of experimental murine malaria with the quassinoid, glaucarubinone].
Prevention and treatment of malaria are endangered by the appearance of chemoresistance against the common anti-malarial drugs by Plasmodium falciparum. Today, only a quinoline derivative, mefloquine, is a safe and effective agent against P. falciparum. An in vitro antiplasmodial activity having been found for the quassinoid glaucarubinone we tested its in vivo therapeutic action on mice infected with a P. berghei strain. At low doses, glaucarubinone retarded mortality by exerting a partial, temporary, inhibition of parasitaemia; its toxicity, however, precludes, further applications at the present time.
D000284:Administration, Oral; D000818:Animals; D004353:Drug Evaluation, Preclinical; D005260:Female; D005900:Glaucarubin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use* / Q000633:toxicity; D007274:Injections, Intraperitoneal; D008288:Malaria / Q000188:drug therapy*; D051379:Mice; D010616:Phenanthrenes / Q000627:therapeutic use*; D010962:Plasmodium berghei
D010616:Phenanthrenes; C015235:glaucarubinone; D005900:Glaucarubin
Essais de traitement du paludisme murin expérimental par un quassinoïde, la glaucarubinone.